Literature DB >> 8709277

Human immunodeficiency virus type 1 membrane fusion mediated by a laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer.

V Litwin1, K A Nagashima, A M Ryder, C H Chang, J M Carver, W C Olson, M Alizon, K W Hasel, P J Maddon, G P Allaway.   

Abstract

Previous studies of human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein-mediated membrane fusion have focused on laboratory-adapted T-lymphotropic strains of the virus. The goal of this study was to characterize membrane fusion mediated by a primary HIV-1 isolate in comparison with a laboratory-adapted strain. To this end, a new fusion assay was developed on the basis of the principle of resonance energy transfer, using HeLa cells stably transfected with gp120/gp41 from the T-lymphotropic isolate HIV-1LA1 or the macrophage-tropic primary isolate HIV-1JR-FL. These cells fused with CD4+ target cell lines with a tropism mirroring that of infection by the two viruses. Of particular note, HeLa cells expressing HIV-1JR-FL gp120/gp41 fused only with PM1 cells, a clonal derivative of HUT 78, and not with other T-cell or macrophage cell lines. These results demonstrate that the envelope glycoproteins of these strains play a major role in mediating viral tropism. Despite significant differences exhibited by HIV-1JR-FL and HIV-1LAI in terms of tropism and sensitivity to neutralization by CD4-based proteins, the present study found that membrane fusion mediated by the envelope glycoproteins of these viruses had remarkably similar properties. In particular, the degree and kinetics of membrane fusion were similar, fusion occurred at neutral pH and was dependent on the presence of divalent cations. Inhibition of HIV-1JR-FL envelope glycoprotein-mediated membrane fusion by soluble CD4 and CD4-IgG2 occurred at concentrations similar to those required to neutralize this virus. Interestingly, higher concentrations of these agents were required to inhibit HIV-1LAI envelope glycoprotein-mediated membrane fusion, in contrast to the greater sensitivity of HIV-1LAI virions to neutralization by soluble CD4 and CD4-IgG2. This finding suggests that the mechanisms of fusion inhibition and neutralization of HIV-1 are distinct.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709277      PMCID: PMC190675          DOI: 10.1128/JVI.70.9.6437-6441.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain.

Authors:  P J Maddon; A G Dalgleish; J S McDougal; P R Clapham; R A Weiss; R Axel
Journal:  Cell       Date:  1986-11-07       Impact factor: 41.582

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Binding of the human retrovirus HTLV-III/LAV/ARV/HIV to the CD4 (T4) molecule: conformation dependence, epitope mapping, antibody inhibition, and potential for idiotypic mimicry.

Authors:  J S McDougal; J K Nicholson; G D Cross; S P Cort; M S Kennedy; A C Mawle
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

4.  Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

Authors:  R D Salter; D N Howell; P Cresswell
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

5.  High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates.

Authors:  E S Daar; X L Li; T Moudgil; D D Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.

Authors:  G P Allaway; K L Davis-Bruno; G A Beaudry; E B Garcia; E L Wong; A M Ryder; K W Hasel; M C Gauduin; R A Koup; J S McDougal
Journal:  AIDS Res Hum Retroviruses       Date:  1995-05       Impact factor: 2.205

7.  A fluorescence enhancement assay of cell fusion.

Authors:  P M Keller; S Person; W Snipes
Journal:  J Cell Sci       Date:  1977-12       Impact factor: 5.285

8.  Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells.

Authors:  B Chesebro; R Buller; J Portis; K Wehrly
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

Review 9.  The CD4 molecule and HIV infection.

Authors:  D R Klatzmann; J S McDougal; P J Maddon
Journal:  Immunodefic Rev       Date:  1990

10.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

View more
  8 in total

1.  Fusion between retinal rod outer segment membranes and model membranes: functional assays and role for peripherin/rds.

Authors:  K Boesze-Battaglia
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  Altering expression levels of human immunodeficiency virus type 1 gp120-gp41 affects efficiency but not kinetics of cell-cell fusion.

Authors:  Janet E Lineberger; Renee Danzeisen; Daria J Hazuda; Adam J Simon; Michael D Miller
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120.

Authors:  Royce A Wilkinson; Chayne Piscitelli; Martin Teintze; Lisa A Cavacini; Marshall R Posner; C Martin Lawrence
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

4.  Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Authors:  W C Olson; G E Rabut; K A Nagashima; D N Tran; D J Anselma; S P Monard; J P Segal; D A Thompson; F Kajumo; Y Guo; J P Moore; P J Maddon; T Dragic
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

5.  Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1.

Authors:  Jose D Murga; Michael Franti; Daniel C Pevear; Paul J Maddon; William C Olson
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

6.  Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

Authors:  T Dragic; A Trkola; S W Lin; K A Nagashima; F Kajumo; L Zhao; W C Olson; L Wu; C R Mackay; G P Allaway; T P Sakmar; J P Moore; P J Maddon
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Crystal structure of the neutralizing Llama V(HH) D7 and its mode of HIV-1 gp120 interaction.

Authors:  Andreas Hinz; David Lutje Hulsik; Anna Forsman; Willie Wee-Lee Koh; Hassan Belrhali; Andrea Gorlani; Hans de Haard; Robin A Weiss; Theo Verrips; Winfried Weissenhorn
Journal:  PLoS One       Date:  2010-05-05       Impact factor: 3.240

8.  Allosteric modulation of the HIV-1 gp120-gp41 association site by adjacent gp120 variable region 1 (V1) N-glycans linked to neutralization sensitivity.

Authors:  Heidi E Drummer; Melissa K Hill; Anne L Maerz; Stephanie Wood; Paul A Ramsland; Johnson Mak; Pantelis Poumbourios
Journal:  PLoS Pathog       Date:  2013-04-04       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.